Aerovate Therapeutics is a high-risk pharmaceutical company based in the USA, with an ESG score of 30.3. Specializing in rare cardiopulmonary diseases, they are developing innovative drugs to enhance patient well-being. Their primary project, AV-101, is an ESG-focused dry powder inhaler for pulmonary arterial hypertension treatment.